Patent application number | Description | Published |
20090017007 | LIQUID FACTOR VII COMPOSITION - Storage-stable aqueous pharmaceutical compositions comprising a Factor VII or Factor Vila polypeptide, a buffering agent, and zinc ions (Zn | 01-15-2009 |
20090030183 | Interferon Beta-Like Molecules - The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide. | 01-29-2009 |
20090088559 | Method for preparing modified polypeptides - Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve
| 04-02-2009 |
20100260741 | Factor VII or VIIa Polypeptide Variants - The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma. | 10-14-2010 |
20100330669 | FVII OR FVIIA VARIANTS - Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237, or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa. | 12-30-2010 |
20110020266 | G-CSF Conjugates - Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF. | 01-27-2011 |
20120135912 | POLYPEPTIDE INHIBITORS OF VLA4 - The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods. | 05-31-2012 |
20120171765 | Factor VII or VIIa - Like Molecules - Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided. | 07-05-2012 |